NKGen Biotech Inc
NASDAQ:NKGN
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
N
|
NKGen Biotech Inc
NASDAQ:NKGN
|
7.5m USD |
Loading...
|
|
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
209B USD |
Loading...
|
|
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR |
Loading...
|
|
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD |
Loading...
|
|
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
104.1B ZAR |
Loading...
|
|
| US |
|
Schlumberger NV
NYSE:SLB
|
76.2B USD |
Loading...
|
|
| US |
B
|
Baker Hughes Co
NASDAQ:BKR
|
58.6B USD |
Loading...
|
|
| CH |
G
|
Galderma Group AG
SIX:GALD
|
34.4B CHF |
Loading...
|
|
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
43.4B USD |
Loading...
|
|
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.5B USD |
Loading...
|
|
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
30.8B ZAR |
Loading...
|
Market Distribution
Other Profitability Ratios
NKGen Biotech Inc
Glance View
NKGen Biotech Inc is a US-based company operating in industry. The company is headquartered in Santa Ana, California. The company went IPO on 2021-05-21. NKGen Biotech, Inc. is a clinical-stage biotechnology company. The firm is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies to treat neurodegenerative and oncological diseases utilizing its (SuperNK) SNK (super-activated) platform. SNK involves the infusion of one’s own activated NK cells into the body to improve immune system function, eliminate diseased or abnormal cells and prevent recurrence. SNK uses pure NK cells harvested from the patient’s blood, activated and infused back into the patient’s body. SNK has a therapeutic potential within the areas of cancer, autoimmune and neurodegenerative diseases. Autologous NK cell immunotherapy is a treatment that provides immune enhancement using pure NK cells harvested from a patient’s body. The company is also focused on conducting clinical trials with its super-activated NK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).
